| Literature DB >> 21573846 |
Rudy Simons1, Jean-Paul Vincken, Loes A M Mol, Susan A M The, Toine F H Bovee, Teus J C Luijendijk, Marian A Verbruggen, Harry Gruppen.
Abstract
The roots of licorice (Glycyrrhiza glabra) are a rich source of flavonoids, in particular, prenylated flavonoids, such as the isoflavan glabridin and the isoflavene glabrene. Fractionation of an ethyl acetate extract from licorice root by centrifugal partitioning chromatography yielded 51 fractions, which were characterized by liquid chromatography-mass spectrometry and screened for activity in yeast estrogen bioassays. One third of the fractions displayed estrogenic activity towards either one or both estrogen receptors (ERs; ERα and ERβ). Glabrene-rich fractions displayed an estrogenic response, predominantly to the ERα. Surprisingly, glabridin did not exert agonistic activity to both ER subtypes. Several fractions displayed higher responses than the maximum response obtained with the reference compound, the natural hormone 17β-estradiol (E(2)). The estrogenic activities of all fractions, including this so-called superinduction, were clearly ER-mediated, as the estrogenic response was inhibited by 20-60% by known ER antagonists, and no activity was found in yeast cells that did not express the ERα or ERβ subtype. Prolonged exposure of the yeast to the estrogenic fractions that showed superinduction did, contrary to E(2), not result in a decrease of the fluorescent response. Therefore, the superinduction was most likely the result of stabilization of the ER, yeast-enhanced green fluorescent protein, or a combination of both. Most fractions displaying superinduction were rich in flavonoids with single prenylation. Glabridin displayed ERα-selective antagonism, similar to the ERα-selective antagonist RU 58668. Whereas glabridin was able to reduce the estrogenic response of E(2) by approximately 80% at 6 × 10(-6) M, glabrene-rich fractions only exhibited agonistic responses, preferentially on ERα.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21573846 PMCID: PMC3124641 DOI: 10.1007/s00216-011-5061-9
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.142
Fig. 1UV profile of the licorice root extract fractionation by CPC. Estrogenically active fractions are indicated
Estrogenic response of CPC fractions from the EA extract of licorice roots
| 3 μg/mL | 10 μg/mL | 0.3 μg/mL | 1.0 μg/mL | 3 μg/mL | 10 μg/mL | 0.3 μg/mL | 1.0 μg/mL | ||
|---|---|---|---|---|---|---|---|---|---|
| Fr | ERα | ERα | ERβ | ERβ | Fr | ERα | ERα | ERβ | ERβ |
| E2 | 100 | 100 | F26a | 38.7 (±1.9) | 93.7 (±6.1) | 95.5 (±3.4) | 151.3 (±15.1) | ||
| F1 | ND | ND | 0.0 (±2.0) | 0.0 (±2.0) | F27a | 36.6 (±0.3) | 90.8 (±2.1) | 74.6 (±5.9) | 176.5 (± 11.8) |
| F2 | ND | 1.1 (±1.2) | 0.0 (±6.5) | 0.0 (±4.9) | F28a | 19.4 (±1.9) | 48.2 (±2.7) | 68.7 (±4.0) | 104.4 (± 8.3) |
| F3 | ND | 4.9 (±0.7) | 1.6 (±1.5) | 0.0 (±4.5) | F29a | 19.9 (±1.3) | 23.0 (±3.9) | 57.2 (±12.5) | 93.5 (±0.6) |
| F4 | ND | 7.8 (±0.8) | 13.4 (±5.0) | 22.4 (±7.7) | F30a | 23.8 (±2.7) | 22.4 (±1.8) | 57.3 (±1.1) | 48.2 (±2.8) |
| F5 | 3.0 (±2.3) | 7.8 (±0.3) | 12.0 (±5.1) | 19.5 (±2.2) | F31 | 25.0 (±1.5) | 34.2 (±1.9) | 25.8 (±8.5) | 40.5 (±17.8) |
| F6 | ND | ND | ND | ND | F32a | 26.8 (±2.3) | 34.5 (±2.0) | 57.4 (±4.7) | 47.4 (±10.7) |
| F7 | 17.1 (±3.0) | 21.0 (±2.7) | 21.4 (±5.6) | 12.2 (±2.2)b | F33a | 32.0 (±1.4) | 38.0 (±0.4) | 50.2 (±9.5) | 36.0 (±3.2) |
| F8 | 10.5 (±2.2) | 21.8 (±6.3) | 17.2 (±2.3) | 58.3 (±3.4) | F34 | 29.6 (±5.3) | 44.9 (±1.3) | 27.7 (±8.8) | 46.1 (±5.2) |
| F9 | 13.3 (±1.5) | 7.1 (±6.4) | 37.8 (±10.0) | 49.1 (±21.5) | F35 | 30.8 (±3.1) | 45.5 (±4.2) | 43.6 (±7.6) | 37.5 (±21.0) |
| F10 | 9.7 (±3.3) | 9.3 (±2.0) | 23.0 (±9.5) | 57.3 (±12.9) | F36 | 42.8 (±2.3) | 42.9 (±6.5) | 19.9 (±2.3) | 45.3 (±2.5) |
| F11 | ND | ND | 46.3 (±12.0) | ND b | F37 | 13.6 (±1.6) | 25.3 (±2.5) | 24.8 (±2.6) | 35.1 (±9.9) |
| F12 | 15.6 (±2.9) | 15.7 (±3.2)b | 30.7 (±0.1) | 77.2 (±7.3) | F38 | 14.8 (±1.7) | 28.8 (±0.5) | 14.2 (±6.8) | 30.8 (±15.4) |
| F13 | ND | ND | 40.3 (±5.0) | 2.4 (±4.9)b | F39 | 19.8 (±1.6) | 32.4 (±2.6) | 21.1 (±4.4) | 45.6 (±14.7) |
| F14 | 4.8 (±4.7) | ND | 42.7 (±6.6) | 73.3 (± 4.1) | F40 | 25.6 (±4.3) | 33.9 (±2.3) | 26.5 (±5.5) | 35.4 (±17.4) |
| F15 | ND | ND | 28.4 (±7.1) | 77.7 (± 1.8) | F41a | 159.9 (±9.5) | 186.9 (±15.0) | 28.3 (±4.9) | 34.9 (±13.5) |
| F16a | 74.8 (±4.0) | 20.4 (±28.9)b | 40.7 (±1.0) | 62.6 (± 2.1) | F42 | 21.6 (±6.0) | 26.2 (±2.2) | 19.8 (±11.0) | 53.8 (±25.5) |
| F17a | 109.1 (±2.3) | 49.3 (±4.4)b | 36.7 (±9.5) | 88.8 (± 8.2) | F43 | 26.5 (±1.8) | 24.7 (±4.3) | 25.4 (±1.2) | 38.9 (±20.0) |
| F18a | 105.3 (±6.2) | 104.6 (±10.5)b | 57.1 (±9.4) | 98.8 (± 15.1) | F44 | 18.9 (±1.9) | 24.6 (±1.5) | 22.7 (±7.3) | 33.8 (±12.2) |
| F19a | 89.1 (±4.2) | 131.2 (±16.2) | 48.3 (±4.6) | 123.8 (±17.1) | F45 | 20.9 (±1.5) | 21.0 (±4.3) | 19.6 (±3.4) | 66.3 (±15.1) |
| F20a | 60.2 (±3.1) | 140.5 (±10.7) | 60.5 (±14.5) | 116.7 (±14.3) | F46 | 16.9 (±1.2) | 20.5 (±3.2) | 18.0 (±11.6) | 73.8 (±7.3) |
| F21a | 71.9 (±8.4) | 125.3 (±1.2) | 45.2 (±3.8) | 145.9 (±25.2) | F47 | 21.2 (±2.9) | 23.3 (±4.2) | 31.0 (±5.1) | 79.4 (±6.1) |
| F22a | 101.4 (±11.6) | 134.1 (±2.7) | 87.0 (±10.3) | 144.4 (±10.7) | F48 | 23.2 (±4.6) | 21.7 (±2.4) | 26.8 (±2.5) | 49.1 (±17.8) |
| F23 | 16.0 (±0.9) | 83.0 (±9.9) | 26.3 (±8.7) | 84.8 (±7.0) | F49 | 26.4 (±0.6) | 26.7 (±0.3) | 16.5 (±3.0) | 82.9 (±4.9) |
| F24a | 79.6 (±1.6) | 156.3 (±14.4) | 103.1 (±2.3) | 159.3 (±23.1) | F50 | 18.8 (±2.7) | 16.7 (±3.2) | 7.3 (±9.3) | 41.3 (±3.1) |
| F25a | 44.2 (±5.7) | 108.6 (±3.9) | 97.9 (±10.6) | 172.8 (±20.7) | F51 | 22.0 (±3.2) | 15.6 (±2.5) | 18.8 (±2.7) | 40.5 (±18.3) |
The estrogenicity toward the ERα and the ERβ was measured at two concentrations. The activity was standardized to the maximum induced response of 2 μM estradiol (100%). Values are the mean ± SD (n = 3). Estrogenic fractions are marked
Fr fraction, ND not detected (estrogenicity values were zero or slightly negative)
aEstrogenically active
bInhibited yeast growth due to cytotoxicity
Fig. 2Transcription activation by ERα (A) and ERβ (B) in response to E2 and subtype-selective antagonists RU58668 (ERα) and R,R-THC (ERβ). The antagonistic activity of both receptor-specific antagonists were assayed in the presence of the EC70 (0.8 nM) and EC90 (0.2 nM) E2 for ERα and ERβ, respectively. Both graphs were normalized to E2. The response of R,R-THC on ERβ for every concentration was lower than the minimum response of E2. This was corrected by normalizing the lowest concentration of R,R-THC to 0%. Values are the mean ± SD (n = 3)
Inhibition of estrogenic response of representative CPC fractions by addition of a subtype-specific antagonist
| Estrogenic activity ERα | Inhibition by RU 58668 | Estrogenic activity ERβ | Inhibition by | |
|---|---|---|---|---|
| E2 | 100 | 60% | 100 | 55% |
| F4 | ND | – | 13.4 (±5.0) | 70% |
| F13 | ND | – | 40.3 (±5.0) | 37% |
| F22 | 101.4 (±11.6) | 52% | 87.0 (±10.3) | 34% |
| F27 | 36.6 (±0.3) | 21% | 74.6 (±5.9) | 61% |
| F30 | 23.8 (±2.7) | 21% | 57.3 (±1.1) | 48% |
| F44 | 18.9 (±1.9) | 30% | 22.7 (±7.3) | 70% |
Inhibition of the estrogenic response of six representative CPC fractions were determined by co-incubation at 1 μg/mL with 6 × 10−6 M RU 58668 for the ERα and 1 μg/mL with 2 × 10−8 M R,R-THC for the ERβ. Values are the mean ± SD (n = 3)
ND not detected
Fig. 3Stabilizing effect of E2, genistein, and several fractions obtained from the licorice root extract on the relative activity measured after 6 and 24 h in the ERβ assay. E , 2 × 10−10 M estradiol; Gen, 2 × 10−7 M genistein; F4 to F44, licorice root fractions obtained by CPC measured at 0.3 μg/mL. Asterisk, negative response
Fractions generated by CPC fractionation and the presence of the main flavonoids in each fraction determined by ultra-high performance LC-MS
| Fraction | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yield (mg) | 110 | 141 | 97 | 136 | 108 | 126 | 211 | 345 | 254 | 156 | 66 | 176 | 157 | 115 | 37 |
| Number of peaks | 20 | 6 | 12 | 25 | 22 | 18 | 7 | 4 | 6 | 6 | 15 | 14 | 17 | 30 | 42 |
| Of which are | |||||||||||||||
| Non-prenylated | 3 | 1 | 2 | 4 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 9 |
| Prenylated | 17 | 5 | 10 | 21 | 20 | 17 | 7 | 4 | 6 | 6 | 15 | 13 | 15 | 26 | 33 |
| Single-prenylated | 13 | 3 | 7 | 9 | 6 | 8 | 4 | 1 | 2 | 3 | 11 | 11 | 13 | 18 | 22 |
| Chain | 7 | 2 | 4 | 6 | 4 | 5 | 2 | 0 | 1 | 2 | 7 | 5 | 9 | 13 | 21 |
| Pyran | 6 | 1 | 3 | 3 | 2 | 3 | 2 | 1 | 1 | 1 | 4 | 6 | 4 | 5 | 1 |
| Double-prenylated | 4 | 2 | 3 | 12 | 14 | 9 | 3 | 3 | 4 | 3 | 4 | 2 | 2 | 8 | 11 |
| Characterization | |||||||||||||||
| Glabrene | ++ | ++ | ++ | ++ | + | ||||||||||
| Glabrone | + | + | ++ | + | |||||||||||
| Glabridin | + | + | ++ | ++ | + | + | + | ||||||||
| Glabrol | + | ++ | ++ | + | + | ||||||||||
| 3′-OH-4′OMe-Ga | + | + | ++ | ++ | |||||||||||
| 4′-OMe-Gb | + | + | ++ | + | |||||||||||
| Hispaglabridin A | + | ++ | ++ | ||||||||||||
| Hispaglabridin B | ++ | ++ | + | ||||||||||||
a4′-O-methyl-glabridin
b3′-hydroxy-4′-O-methyl-glabridin
Fig. 4Main flavonoids identified in CPC fractions 6–21 obtained from the EA extract of licorice root
Fig. 5Antagonistic activity of glabridin on the estrogenic response in the ERα yeast estrogen bioassay